Ifg Advisory, LLC Abb Vie Inc. Transaction History

Ifg Advisory, LLC

$1.54 Billion
Q3 2024

A detailed history of Ifg Advisory, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Ifg Advisory, LLC holds 37,578 shares of ABBV stock, worth $6.37 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares

37,578

Previous 37,195 1.03%

Holding current value

$6.37 Million

Previous $6.38 Million 16.32%

% of portfolio

0.48%

Previous 0.42%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	BUY	$163.84 - $199.33 $62,750 - $76,343	383 Added 1.03%	37,578 $7.42 Million
Q2 2024 Jul 30, 2024	BUY	$154.79 - $180.76 $154,944 - $180,940	1,001 Added 2.77%	37,195 $6.38 Million
Q1 2024 May 06, 2024	SELL	$159.82 - $182.1 $177,879 - $202,677	-1,113 Reduced 2.98%	36,194 $6.59 Million
Q4 2023 Jan 17, 2024	BUY	$137.6 - $154.97 $1.79 Million - $2.02 Million	13,022 Added 53.62%	37,307 $5.78 Million
Q3 2023 Nov 13, 2023	BUY	$133.59 - $154.65 $92,577 - $107,172	693 Added 2.94%	24,285 $3.62 Million
Q2 2023 Jul 21, 2023	SELL	$132.51 - $164.9 $123,764 - $154,016	-934 Reduced 3.81%	23,592 $3.18 Million
Q1 2023 Apr 26, 2023	BUY	$144.61 - $166.54 $301,367 - $347,069	2,084 Added 9.29%	24,526 $3.91 Million
Q4 2022 Jan 31, 2023	SELL	$138.31 - $165.87 $835,669 - $1 Million	-6,042 Reduced 21.21%	22,442 $3.63 Million
Q3 2022 Oct 28, 2022	BUY	$134.21 - $153.93 $964,433 - $1.11 Million	7,186 Added 33.74%	28,484 $3.82 Million
Q2 2022 Aug 04, 2022	SELL	$137.62 - $174.96 $515,937 - $655,925	-3,749 Reduced 14.97%	21,298 $3.26 Million
Q1 2022 May 04, 2022	SELL	$131.98 - $163.75 $171,310 - $212,547	-1,298 Reduced 4.93%	25,047 $4.06 Million
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $262,666 - $332,348	2,445 Added 10.23%	26,345 $3.57 Million
Q3 2021 Oct 12, 2021	BUY	$106.4 - $120.78 $60,754 - $68,965	571 Added 2.45%	23,900 $2.58 Million
Q2 2021 Jul 21, 2021	SELL	$105.21 - $117.21 $368,550 - $410,586	-3,503 Reduced 13.06%	23,329 $2.63 Million
Q1 2021 Apr 19, 2021	BUY	$102.3 - $112.62 $29,564 - $32,547	289 Added 1.09%	26,832 $2.9 Million
Q4 2020 Feb 08, 2021	SELL	$80.49 - $108.67 $689,718 - $931,193	-8,569 Reduced 24.4%	26,543 $2.84 Million
Q3 2020 Nov 02, 2020	BUY	$85.91 - $100.83 $96,305 - $113,030	1,121 Added 3.3%	35,112 $3.08 Million
Q2 2020 Aug 10, 2020	BUY	$73.37 - $98.18 $318,645 - $426,395	4,343 Added 14.65%	33,991 $3.34 Million
Q1 2020 May 11, 2020	BUY	$64.5 - $97.79 $626,682 - $950,127	9,716 Added 48.75%	29,648 $2.26 Million
Q4 2019 Feb 07, 2020	SELL	$72.13 - $90.25 $24,596 - $30,775	-341 Reduced 1.68%	19,932 $1.76 Million
Q3 2019 Nov 06, 2019	BUY	$62.98 - $75.72 $175,966 - $211,561	2,794 Added 15.98%	20,273 $1.54 Million
Q2 2019 Aug 06, 2019	BUY	$65.7 - $83.98 $21,549 - $27,545	328 Added 1.91%	17,479 $1.27 Million
Q1 2019 May 08, 2019	BUY	$77.14 - $90.79 $26,073 - $30,687	338 Added 2.01%	17,151 $1.38 Million
Q4 2018 Feb 07, 2019	SELL	$77.85 - $96.01 $1.25 Million - $1.54 Million	-16,060 Reduced 48.85%	16,813 $1.55 Million
Q3 2018 Nov 05, 2018	BUY	$88.91 - $98.84 $93,444 - $103,880	1,051 Added 3.3%	32,873 $3.11 Million
Q2 2018 Aug 02, 2018	SELL	$89.78 - $106.23 $1,167 - $1,380	-13 Reduced 0.04%	31,822 $2.95 Million
Q1 2018 Apr 26, 2018	SELL	$92.01 - $123.21 $361,047 - $483,476	-3,924 Reduced 10.97%	31,835 $0
Q4 2017 Feb 01, 2018	SELL	$89.56 - $98.21 $962,053 - $1.05 Million	-10,742 Reduced 23.1%	35,759 $3.46 Million
Q4 2017 Jan 29, 2018	BUY	$89.56 - $98.21 $4.16 Million - $4.57 Million	46,501	46,501 $3.56 Million

Others Institutions Holding ABBV

# of Institutions

3,817

Shares Held

1.25B

Call Options Held

13M

Put Options Held

10M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $300B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifg Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ifg Advisory, LLC with notifications on news.

Account